Showing 1 - 6 results of 6 for search 'Naoki Takezako', query time: 0.07s
Refine Results
-
1
Eight‐color multiparameter flow cytometry (EuroFlow‐NGF) is as sensitive as next‐generation sequencing in detecting minimal/measurable residual disease in autografts of patients wi... by Ryota Urushihara, Naoki Takezako, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kenji Satou, Shinji Nakao, Hiroyuki Takamatsu
Published 2023-02-01
Article -
2
Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin by Hideo Wada, Kazuo Kawasugi, Goichi Honda, Noriaki Kawano, Toshimasa Uchiyama, Seiji Madoiwa, Naoki Takezako, Kei Suzuki, Yoshinobu Seki, Takayuki Ikezoe, Toshiaki Iba, Kohji Okamoto
Published 2023-01-01
Article -
3
Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular c... by Kazuo Kawasugi, Hideo Wada, Goichi Honda, Noriaki Kawano, Toshimasa Uchiyama, Seiji Madoiwa, Naoki Takezako, Kei Suzuki, Yoshinobu Seki, Takayuki Ikezoe, Toshiaki Iba, Kohji Okamoto
Published 2021-02-01
Article -
4
Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatmen... by Seki Yoshinobu MD, PhD, Goichi Honda PhD, Noriaki Kawano MD, PhD, Toshimasa Uchiyama MD, PhD, Kazuo Kawasugi MD, PhD, Seiji Madoiwa MD, PhD, Naoki Takezako MD, PhD, Ikezoe Takayuki MD, PhD, Hideo Wada MD, PhD
Published 2021-12-01
Article -
5
Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis by Hideo Wada MD, PhD, Goichi Honda PhD, Noriaki Kawano MD, PhD, Toshimasa Uchiyama MD, PhD, Kazuo Kawasugi MD, PhD, Seiji Madoiwa MD, PhD, Naoki Takezako MD, PhD, Kei Suzuki MD, PhD, Yoshinobu Seki MD, PhD, Takayuki Ikezoe MD, PhD, Toshiaki Iba MD, PhD, Kohji Okamoto MD, PhD
Published 2020-08-01
Article -
6
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX by Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet-Loiseau, Saad Z. Usmani
Published 2018-12-01
Article